Parliament Question: Tata Memorial Hospitals

GOVERNMENT OF INDIA DEPARTMENT OF ATOMIC ENERGY LOK SABHA UNSTARRED QUESTION NO - 1763 ANSWERED ON 29/07/2026 TATA MEMORIAL HOSPITALS 1763. SHRI RAJESH VERMA SMT SHAMBHAVI DR LATA WANKHEDE Will the PRIME MINISTER be pleased to state:- (a) whether the Government has achieved remarkable success in expanding its network of affordable cancer care hospitals bringing world-class oncological treatment to the common man; (b) if so, the details of the new Tata Memorial Hospital branches and allied cancer institutes operationalised to assist poor rural patients during 2025-26, State-wise; (c) the details of the total number of economically underprivileged citizens who have benefited from highly subsidized or completely free radiation therapy and diagnostic services at these central facilities; (d) whether indigenous development of advanced radio-pharmaceuticals has significantly reduced the cost of cancer diagnosis and treatment for middle-class households and if so, the details thereof; and (e) the steps taken by the Government to further integrate these specialised atomic energy medical centers with the Ayushman Bharat scheme to guarantee zero-cost healthcare for our most vulnerable families? ANSWER THE MINISTER OF STATE FOR PERSONNEL, PUBLIC GRIEVANCES & PENSIONS AND PRIME MINISTER’S OFFICE (DR. JITENDRA SINGH) (a) The Tata Memorial Centre (TMC) under the administrative control of Department of Atomic Energy (DAE) with a mandate to provide comprehensive cancer care to one and all, through its motto of excellence in Service, Education andResearch. TMC being a premier cancer centre in the country, provides leadership in guiding the national/international policy and strategy for cancer care. TMC has expanded its network of affordable cancer care hospitals bringing world-class oncological treatment to the common man as under: Sr. Name of the Hospital City, State No. 1 Tata Memorial Hospital Mumbai, Maharashtra Advanced Centre for Treatment, Research and Navi Mumbai, 2 Education in Cancer (ACTREC) Maharashtra Mahamana Pt. Madan Mohan Malaviya Cancer Centre Varanasi, Uttar Pradesh 3 (MPMMCC) at Varanasi Homi Bhabha Cancer Hospital Varanasi, Uttar Pradesh Visakhapatnam, Andhra 4 Homi Bhabha Cancer Hospital & Research Centre Pradesh Homi Bhabha Cancer Hospital & Research Centre New Chandigarh, Punjab 5 Homi Bhabha Cancer Hospital Sangrur, Punjab 6 Dr. B. Borooah Cancer Institute (BBCI) Guwahati, Assam 7 Homi Bhabha Cancer Hospital and Research Centre Muzaffarpur, Bihar 8 Platinum Jubilee Block Mumbai, Maharashtra Integrated Centre for Treatment, Research, and Khopoli, Raigad, 9 Education in Cancer (ICTREC) Maharashtra 10 Homi Bhabha Cancer Hospital Bhubaneswar, Odisha (b) Out of 11 TMC hospitals as listed above, 2 new hospitals, namely HBCH, Sangrur (Punjab) and HBCH&RC, Muzaffarpur (Bihar) are fully functional, and located in the rural areas. HBCH&RC, Muzaffarpur (Bihar) was inaugurated in 2025.(c) Following is the statistics with reference to number of economically underprivileged citizens benefitted from the cancer treatment at TMC hospitals: Radiotherapy Sr. Laboratory Nuclear Name of the Hospital (No of Radiology No. Investigations Medicine patients) 1 Tata Memorial Hospital 5242 232897 89898 13513 Advanced Centre for Treatment, Research and 2 1550 1904113 77578 1873 Education in Cancer (ACTREC) Homi Bhabha Cancer Hospital and Mahamana 3 Pt. Madan Mohan 3302 835235 95673 11934 Malaviya Cancer Centre (MPMMCC) at Varanasi Homi Bhabha Cancer 4 Hospital & Research 3089 1134573 56778 6212 Centre, Punjab Homi Bhabha Cancer 5 Hospital & Research 1587 8683 15789 1808 Centre, Visakhapatnam Homi Bhabha Cancer 6 Hospital & Research 1044 161069 4504 -- Centre, Muzaffapur Dr. B. Borooah Cancer 1916 92797 39709 3962 7 Institute (BBCI)(d) Yes. The indigenous development of therapeutic radiopharmaceuticals and brachytherapy sources based on radioisotopes such as Lutetium-177 (Lu-177), Yttrium- 90 (Y-90) and Ruthenium-106 (Ru-106) available from Dhruva reactor, BARC has significantly improved the affordability of cancer treatment in India. These products are available at substantially lower prices than their imported counterparts. For example, Lu-177 radiopharmaceuticals such as 177Lu-DOTATATE and 177Lu-PSMA-617 for treatment of neuroendocrine tumours and prostate cancer are offered at about one-half to one-third the cost of equivalent imported products. Similarly, Yttrium-90 glass microspheres used for liver cancer therapy are available at nearly one-sixth the price of comparable international products, while Ruthenium-106 plaques for the treatment of eye cancer cost less than one-fourth of imported alternatives. In addition, diagnostic and therapeutic radioisotope-based products including Mo-99/Tc-99m generators, Tc-99m cold kits and I-131radiopharmaceuticals manufactured and supplied by the Department play a crucial role in regulating the market prices ensuring the availability of affordable nuclear medicine products in the country. (e) The TMC has integrated all its constituent units with Ayushman Bharat scheme and respective State health schemes. *****